 |
0 Diseases |  |
10 Trials |
|
10 Trials |  |
41 News |  |
| «12...1213141516171819202122...2627» |
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
[VIRTUAL] Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1783;
P3
Indirect treatment comparison indicated efficacy and safety of CAB LA + RPV LA Q2M is not different from BIC/FTC/TAF. These regimens will be further compared in a randomized head-to-head non-inferiority trial (SOLAR, NCT04542070).
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] Coverage, Cost Sharing, and Out-of-Pocket Costs for Single-Tablet HIV Antiretroviral Regimens in Qualified Health Plans in the United States, 2018-2020 () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1778;
Over time, coverage of the newer STR increased, but many QHPs in EHE jurisdictions still required coinsurance. Access to newer ART regimens may be slowed by delayed QHP coverage or complex negotiations with manufacturers about formulary inclusion as ART options become more competitive, even if patients are insulated from cost differences.
- clarithromycin / Generic mfg.
[VIRTUAL] Central nervous system involvement in disseminated Mycobacterium avium complex infection in patients with newly diagnosed HIV () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1739;
All patients presented CNS symptoms and normal CSF characteristics. In our setting, patients with suspected disseminated MAC infection CD4 counts < 50 cells/mm 3 might represent a specific population that could benefit from routine targeted diagnostic test at presentation in order to establish CNS involvement.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] High Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in African American Adults with HIV Including Those with Preexisting Resistance, Viral Blips, and Suboptimal Adherence () - Oct 6, 2021 - Abstract #IDWeek2021IDWeek_1194;
Virologic suppression was maintained through W72 of B/F/TAF treatment, including those with preexisting resistance, viral blips, and suboptimal adherence. Continued HIV suppression and absence of treatment-emergent resistance demonstrate the efficacy of B/F/TAF in African Americans regardless of adherence or preexisting resistance to NNRTIs, PIs, or non-tenofovir NRTIs.
- || Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Clinical, Observational data, Retrospective data, Journal, Real-world evidence: Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. (Pubmed Central) - Oct 3, 2021
Treatment-related adverse events occurred in 51 (15%) patients (all Grade 1-2) and led to 8 discontinuations.In this real-world cohort, switching to B/F/TAF was associated with maintenance of virologic control, and avoidance of DDIs in a large proportion of patients. These data support use of B/F/TAF as a treatment option in older PLWH.
- |||| Sunlenca (lenacapavir) / Gilead
New P2 trial, Combination therapy: Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV (clinicaltrials.gov) - Sep 21, 2021
P2, N=75, Not yet recruiting, Sponsor: Gilead Sciences
- | bictegravir (GS-9883) / Gilead, Vemlidy (tenofovir alafenamide) / Gilead
Enrollment change, Trial withdrawal: A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects (clinicaltrials.gov) - Sep 20, 2021
P4, N=0, Withdrawn, Sponsor: Yale University
These data support use of B/F/TAF as a treatment option in older PLWH. N=24 --> 0 | Not yet recruiting --> Withdrawn
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Two different clinical courses in 2 HIV-positive patients pre-diagnosed with coxarthrosis (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_873;
TDF/FTC and EFV therapies were initiated...BIC/FTC/TAF therapy was initiated...Contrast Involvement of the femoral head Orthopedic prosthetic surgeries are commonly used for patients diagnosed with coxarthrosis. The diagnosis of coxarthrosis should carefully be examined in HIV-positive patients before the patient is referred for surgery.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Malabsorption induced multi class HIV drug resistance and viral logical failure (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_867;
We hypothesise that disseminated MAI induced intestinal failure resulting in ART malabsorption. We propose that in patients such as this, therapeutic drug monitoring and a low threshold for parenteral ART administration may reduce the risk of developing new drug resistance and virological failure.
- Descovy (emtricitabine/tenofovir alafenamide) / Gilead
A patient with HIV-1 on Descovy®, atazanavir and ritonavir presenting with general lethargy (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_860;
If patients on PIs present with nonspecific symptoms consider adrenal insufficiency and explore Corticosteroid use. Given that in 2016 approximately 25% of people living with HIV in England were Black African, and the high usage of skin bleaching creams amongst this group, this is potentially an underrecognized drug-drug interaction.
- Cytovene (ganciclovir) / Roche, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
A case of mycobacterial infection complicated by CMV-driven haemophagocytic lymphohistiocytosis (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_858;
He was commenced on Bictegravir/Emtricitabine/Tenofovir alafenamide and PCP prophylaxis...He was commenced on IV ganciclovir and IV Immunoglobulin to treat HLH-MAS secondary to CMV infection...Broad spectrum anti-mycobacterial treatment was commenced whilst characterisation was awaited and ART was simplified to Lamivudine/Dolutegravir to avoid drug-drug interactions...Blood parameters for HLH resolved quickly with CMV treatment and limited immunomodulation. The case also illustrates the value of Bone Marrow biopsy in diagnosing opportunistic infections and the ongoing need for education around HIV acquisition in traditionally well informed groups.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Persistence on guideline-recommended HIV treatment: comparison among US Medicaid beneficiaries newly initiating treatment with single- versus multiple-tablet regimens (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_839;
Among adult US Medicaid beneficiaries living with HIV and newly prescribed ART, persistence was statistically significantly higher among STR initiators compared to MTR initiators. Amongst those on STRs, specifically B/F/TAF, persistence was significantly higher as compared to MTRs (F/TDF+DTG and F/TAF+DTG).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bioavailability of solid vs. dissolved vs. crushed single-tablet of bictegravir / emtricitabine / tenofovir alafenamide in HIV negative volunteers: the SOLUBIC study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_614;
P1
Even if dissolved and crushed tablets of B/F/TAF did not met all the criteria for bioequivalence, the dissolved tablet was close to this result. Therefore, we suggest that B/F/TAF could be given dissolved in water for patients with swallowing difficulties, provided that residual dosages are carried out in the event of prolonged administration.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_606;
These results confirm safety and efficacy of B/F/TAF in those who switch from a DTG-containing regimen. In Study 1489, 315 participants were randomized to DTG/ABC/3TC; 254 (81%) entered the OLE.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_595;
Effectiveness was demonstrated across key subgroups (females, older participants, late presenters). Importantly, there were no new or unexpected safety findings.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Patient-reported outcome (PRO) measures at 12 months (12M) in a real-world cohort of people living with HIV (PLWH) with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_588;
In this real-world cohort of PLWH with a high prevalence of comorbidities (and in the setting of a global pandemic), patient-reported adherence, physical/mental health, bothersome symptoms, and treatment satisfaction were maintained/showed improvements during 12M of B/F/TAF treatment. Funding: Gilead Sciences
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study) (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_585;
Our preliminary data showed that switching from EFV/FTC/TDF to BIC/FTC/TAF was highly effective and safe with 99% viral suppression and significant increase of CD4 cell count. A mild increase in blood creatinine was observed probably due to the inhibition of hOCT2 mediated by BIC.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Symptom burden among adult people living with HIV in Taiwan (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_581;
While gastrointestinal symptoms have significantly improved with switch to BIC/FTC/TAF, most of our participants continued to experience at least one symptom. Multidisciplinary approach with further evaluation and interventions are warranted to improve the long-term quality of life of PLWH.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Impact of switch from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_578;
Our results suggest that switching from EFV/F/TDF to B/F/TAF significantly improves psychiatric symptoms and sleep quality. Neurocognitive performance remained stable, although a decline on NPZ-12 and in specific domains was observed.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_570;
Biktarvy suppressed HIV in older treatment-experienced males and was generally well tolerated. Further evaluation in older patients is needed.
- bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Gender-related differences in safety after switching to BICTEGRAVIR/TAF/FTC in “real life” (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_569;
This findings could be related to significant baseline gender-related differences. All patients switching to BICTEGRAVIR/TAF/FTC (May 8, 2019-BICTEGRAVIR/TAF/FTC availability-, Dec 31, 2020).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Feasibility, efficacy and safety of a rapid antiretroviral therapy starting B/F/TAF in advanced HIV disease (RAINBOW study) (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_565;
All patients switching to BICTEGRAVIR/TAF/FTC (May 8, 2019-BICTEGRAVIR/TAF/FTC availability-, Dec 31, 2020). Preliminary results of this study provide the first evidence supporting the feasibility of B/F/TAF test and treat strategy in advanced HIV subjects.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
A simplified approach to antiretroviral therapy with biktarvy among inner-city vulnerable residents with HIV infection: living up to the promise of 90-90-90 (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_564;
A disproportionate number of vulnerable inner-city residents exhibit incomplete responses to antiretroviral therapy. We have shown that this can be successfully addressed through the administration of simpler, more potent antiretroviral regimens in the context of patient-centered multidisciplinary models of care.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Intermittent bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) maintains viral suppression in real life in controlled HIV-infected patients (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_561;
Eighty-seven patients were included, with median age: 52 years (IQR 45–59), ART duration: 13 years (6–22), duration of virological suppression: 9 years (IQR 3–13), CD4: 648/mm3 (420–837) [Table]. All had pVL <50 copies/mL at study entry.
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Safety and efficacy of E/C/F/TAF switch followed by SOF/VEL antiviral HCV therapy followed by B/F/TAF simplification in HIV-HCV co-infected subjects receiving opioid agonist therapy with methadone or buprenorphine / naloxone (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_553;
Participants on suppressive HIV antiretroviral therapy with HCV co-infection receiving methadone or buprenorphine/naloxone were switched to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), and 12 weeks later were initiated on sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks. The use of single tablet regimens ECF/TAF, SOF/VEL, and B/F/TAF in HIV-HCV co-infected persons receiving OAT is safe, well-tolerated, and efficacious.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Low-level viraemia and virologic failure among people living with HIV who switched to coformulated bictegravir, emtricitabine and tenofovir alafenamide (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_551;
The use of single tablet regimens ECF/TAF, SOF/VEL, and B/F/TAF in HIV-HCV co-infected persons receiving OAT is safe, well-tolerated, and efficacious. The incidence rates of LLV and VF with switch to coformulated BIC/FTC/TAF were low in the real-world setting.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Efficacy and safety of using bictegravir / emtricitabine / tenofovir alafenamide (BIC/FTC/TAF) in a test and treat model: the FAST Study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_545;
These results suggest that BIC/FTC/TAF is safe and effective for same-day ART initiation in a test-and-treat setting. Follow-up will continue until W48.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Effect of second generation INSTI on weight and lipid profile in patients with HIV infection (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_542;
The increase in cholesterol levels were seen in both groups of patients. Further studies are needed to corroborate these observations From 161 patients who were invited, only 144 patients had complete measurments.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Long-term efficacy of bictegravir/emtricitabine/tenofovir alafenamide after switch from boosted protease inhibitor-based regimens including in those with preexisting resistance and viral blips (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_535;
Further studies are needed to corroborate these observations From 161 patients who were invited, only 144 patients had complete measurments. Long-term suppression for ≥2 years and the absence of treatment-emergent resistance, including in those with preexisting resistance or viral blips, demonstrate the durable efficacy of B/F/TAF.
- In vitro forgiveness of oral and long-acting INSTI-containing regimens at drug concentrations simulating variable adherence (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_526;
When simulating multiple missed doses of daily drug, all oral regimens had some VB and developed resistance; however, BIC+FTC+TAF had the highest forgiveness and barrier to resistance. Further studies with CAB+RPV are needed to understand forgiveness at the PK tail of this long-acting regimen.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Prevalence and risk factors of preexisting TAMs in clinical trial participants and sustained viral suppression after switching to bictegravir/emtricitabine/tenofovir alafenamide (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_522;
Preexisting TAMs were detected in 10% of participants and were associated with longer time on ART and other preexisting resistance. Maintenance of virologic suppression, and the absence of treatment-emergent resistance, demonstrate the durable efficacy of B/F/TAF, regardless of preexisting TAMs.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients (Virtual room 1 (online only)) - Sep 18, 2021 - Abstract #EACS2021EACS_454;
No clinically significant change was observed for lipid profile and glucose values. Female gender and not Caucasian ethnicity were associated to WG.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] Efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in patients with pre-existing nrti resistances: real world data (Virtual room 1 (online only)) - Sep 18, 2021 - Abstract #EACS2021EACS_452;
These results confirm the robustness of this combination. Results on ITT are penalized for lost visits due to the pandemic.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
[VIRTUAL] Virological response and resistance profile in virologically suppressed HIV-1 infected individuals switching to a bictegravir based treatment in clinical practice (Virtual room 1 (online only)) - Sep 18, 2021 - Abstract #EACS2021EACS_443;
Further analyses with longer follow-up are needed to confirm these findings. Overall, 284 individuals exposed to cART since a median (IQR) time of 8 (4–13) years and virologically suppressed for a median (IQR) time of 7 (3–9) years were analyzed (Table1).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Two different clinical courses in 2 HIV-positive patients pre-diagnosed with coxarthrosis (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_406;
TDF/FTC and EFV therapies were initiated...BIC/FTC/TAF therapy was initiated...Contrast Involvement of the femoral head Orthopedic prosthetic surgeries are commonly used for patients diagnosed with coxarthrosis. The diagnosis of coxarthrosis should carefully be examined in HIV-positive patients before the patient is referred for surgery.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Malabsorption induced multi class HIV drug resistance and viral logical failure (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_400;
We hypothesise that disseminated MAI induced intestinal failure resulting in ART malabsorption. We propose that in patients such as this, therapeutic drug monitoring and a low threshold for parenteral ART administration may reduce the risk of developing new drug resistance and virological failure.
- Descovy (emtricitabine/tenofovir alafenamide) / Gilead
A patient with HIV-1 on Descovy®, atazanavir and ritonavir presenting with general lethargy (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_393;
If patients on PIs present with nonspecific symptoms consider adrenal insufficiency and explore Corticosteroid use. Given that in 2016 approximately 25% of people living with HIV in England were Black African, and the high usage of skin bleaching creams amongst this group, this is potentially an underrecognized drug-drug interaction.
- Cytovene (ganciclovir) / Roche, Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
A case of mycobacterial infection complicated by CMV-driven haemophagocytic lymphohistiocytosis (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_391;
He was commenced on Bictegravir/Emtricitabine/Tenofovir alafenamide and PCP prophylaxis...He was commenced on IV ganciclovir and IV Immunoglobulin to treat HLH-MAS secondary to CMV infection...Broad spectrum anti-mycobacterial treatment was commenced whilst characterisation was awaited and ART was simplified to Lamivudine/Dolutegravir to avoid drug-drug interactions...Blood parameters for HLH resolved quickly with CMV treatment and limited immunomodulation. The case also illustrates the value of Bone Marrow biopsy in diagnosing opportunistic infections and the ongoing need for education around HIV acquisition in traditionally well informed groups.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
Persistence on guideline-recommended HIV treatment: comparison among US Medicaid beneficiaries newly initiating treatment with single- versus multiple-tablet regimens (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_372;
Among adult US Medicaid beneficiaries living with HIV and newly prescribed ART, persistence was statistically significantly higher among STR initiators compared to MTR initiators. Amongst those on STRs, specifically B/F/TAF, persistence was significantly higher as compared to MTRs (F/TDF+DTG and F/TAF+DTG).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bioavailability of solid vs. dissolved vs. crushed single-tablet of bictegravir / emtricitabine / tenofovir alafenamide in HIV negative volunteers: the SOLUBIC study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_147;
P1
Even if dissolved and crushed tablets of B/F/TAF did not met all the criteria for bioequivalence, the dissolved tablet was close to this result. Therefore, we suggest that B/F/TAF could be given dissolved in water for patients with swallowing difficulties, provided that residual dosages are carried out in the event of prolonged administration.
- Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Outcomes 48 weeks after switching from DTG/ABC/3TC or DTG+F/TAF to B/F/TAF (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_139;
These results confirm safety and efficacy of B/F/TAF in those who switch from a DTG-containing regimen. In Study 1489, 315 participants were randomized to DTG/ABC/3TC; 254 (81%) entered the OLE.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV (PLWH): 12-month (12M) effectiveness, persistence, and safety in a multi-country cohort study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_128;
Effectiveness was demonstrated across key subgroups (females, older participants, late presenters). Importantly, there were no new or unexpected safety findings.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Patient-reported outcome (PRO) measures at 12 months (12M) in a real-world cohort of people living with HIV (PLWH) with a high prevalence of comorbidities receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_121;
In this real-world cohort of PLWH with a high prevalence of comorbidities (and in the setting of a global pandemic), patient-reported adherence, physical/mental health, bothersome symptoms, and treatment satisfaction were maintained/showed improvements during 12M of B/F/TAF treatment. Funding: Gilead Sciences
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Efficacy and safety of switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in virologically-suppressed HIV patients (EBONY Study) (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_118;
Our preliminary data showed that switching from EFV/FTC/TDF to BIC/FTC/TAF was highly effective and safe with 99% viral suppression and significant increase of CD4 cell count. A mild increase in blood creatinine was observed probably due to the inhibition of hOCT2 mediated by BIC.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Symptom burden among adult people living with HIV in Taiwan (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_114;
While gastrointestinal symptoms have significantly improved with switch to BIC/FTC/TAF, most of our participants continued to experience at least one symptom. Multidisciplinary approach with further evaluation and interventions are warranted to improve the long-term quality of life of PLWH.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Impact of switch from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_111;
Our results suggest that switching from EFV/F/TDF to B/F/TAF significantly improves psychiatric symptoms and sleep quality. Neurocognitive performance remained stable, although a decline on NPZ-12 and in specific domains was observed.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Tolerability and antiviral activity of bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) treatment switch in patients aged 55 years or older with HIV: the BIO study (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_103;
Biktarvy suppressed HIV in older treatment-experienced males and was generally well tolerated. Further evaluation in older patients is needed.
- bictegravir (GS-9883) / Gilead, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Gender-related differences in safety after switching to BICTEGRAVIR/TAF/FTC in “real life” (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_102;
This findings could be related to significant baseline gender-related differences. All patients switching to BICTEGRAVIR/TAF/FTC (May 8, 2019-BICTEGRAVIR/TAF/FTC availability-, Dec 31, 2020).
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Feasibility, efficacy and safety of a rapid antiretroviral therapy starting B/F/TAF in advanced HIV disease (RAINBOW study) (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_98;
All patients switching to BICTEGRAVIR/TAF/FTC (May 8, 2019-BICTEGRAVIR/TAF/FTC availability-, Dec 31, 2020). Preliminary results of this study provide the first evidence supporting the feasibility of B/F/TAF test and treat strategy in advanced HIV subjects.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
A simplified approach to antiretroviral therapy with biktarvy among inner-city vulnerable residents with HIV infection: living up to the promise of 90-90-90 (eLibrary) - Sep 18, 2021 - Abstract #EACS2021EACS_97;
A disproportionate number of vulnerable inner-city residents exhibit incomplete responses to antiretroviral therapy. We have shown that this can be successfully addressed through the administration of simpler, more potent antiretroviral regimens in the context of patient-centered multidisciplinary models of care.